Collegium Pharmaceutical Inc. (COLL) Sets New 12-Month Low at $11.32
Shares of Collegium Pharmaceutical Inc. (NASDAQ:COLL) hit a new 52-week low on Tuesday . The stock traded as low as $11.32 and last traded at $11.35, with a volume of 48,801 shares traded. The stock had previously closed at $11.86.
Several analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $30.00 price objective (up from $28.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 26th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $26.00 target price on shares of Collegium Pharmaceutical in a research report on Thursday, May 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $29.25.
The stock’s market capitalization is $291.73 million. The company’s 50-day moving average is $12.68 and its 200-day moving average is $16.32.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.08. Analysts anticipate that Collegium Pharmaceutical Inc. will post ($3.25) EPS for the current fiscal year.
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.